Just lately, there was a small research printed that steered there’s a hyperlink between Novo Nordisk’s (NYSE:NVO) weight problems drug semaglutide and a watch dysfunction known as NAION. Nevertheless, one other research emerged indicating that utilizing GLP-1 medication and metformin is linked to a decrease danger of sure obesity-related cancers in sufferers with Kind 2 diabetes.
Printed Friday on the JAMA Community Open web site, the research revealed that sufferers taking GLP-1 medication or metformin had a considerably diminished danger of growing ten obesity-associated cancers in comparison with these utilizing insulin. Nevertheless, researchers famous that GLP-1 medication didn’t decrease the danger greater than metformin.
The research, which analyzed digital healthcare data of about 1.7 million Kind 2 diabetes sufferers prescribed GLP-1 medication, metformin, or insulin between 2005 and 2018, discovered statistically important danger reductions in GLP-1 customers for cancers similar to gallbladder, pancreatic, ovarian, colorectal, and kidney most cancers, amongst others. The GLP-1 medication included within the research had been first-generation medicines like Novo Nordisk’s Victoza and Ozempic (semaglutide) however didn’t embody Eli Lilly’s (NYSE:LLY) Mounjaro, accepted in 2022.
Is Novo Nordisk a Purchase, Promote, or Maintain?
Turning to Wall Avenue, analysts have a Average Purchase consensus score on NVO inventory based mostly on six Buys, one Maintain, and one Promote assigned up to now three months, as indicated by the graphic under. Moreover, the common NVO value goal of $142.36 per share implies that shares are pretty valued.
